cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.48597/ar5f-d3v3
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.6084/m9.figshare.28367569.v1
title: Fetuin-B and oxidative stress disrupt placental trophoblasts during maternal undernourishment

description: Insufficient nutrition during pregnancy can lead to negative health outcomes for both mother and foetus. Maternal undernourishment (MUN) can be due to many factors like hyperemesis gravidarum or poor access to nutrition. Just as MUN can affect the mother and foetus, it can adversely affect the vital placental interface between the two. We suspect an observed increase in fetuin-B and oxidative stress in MUN placentas could be major players responsible for the placental insufficiency often seen with MUN. To establish a model of MUN during pregnancy, a reduced protein chow was fed to pregnant dams at a caloric deficit. We examined the MUN placentas and the downstream effects of fetuin-B and oxidative stress at the whole organ and trophoblast levels. We examined fetuin-B’s role in trophoblast pathology by measuring apoptosis, proliferation, TLR4 activation, expression of NF-ΚB p65, oxidative stress, and mitochondrial superoxide production. The effects of MUN and fetuin-B on mitochondrial superoxide production, antioxidant levels, metabolism, and electron transport chain complex activity were compared directly. Pharmaceutical interventions were utilised to narrow down specific pathways involved. Studies indicated that MUN and oxidative stress upregulated fetuin-B in the placenta. This relationship displayed a positive feedback loop as fetuin-B, in turn, promoted oxidative stress through activation of TLR4. Consequently, MUN, fetuin-B, and oxidative stress promoted apoptosis and reduced proliferative expansion of trophoblast, thereby reducing their quantity. MUN and fetuin-B reduced mitochondrial metabolism and function, promoting mitochondrial dysregulation and superoxide generation in MUN trophoblasts. Our study sheds light on the mechanisms responsible for MUN-induced placental insufficiency while identifying therapeutic agents as possible add-on interventions. Inadequate nutrition during pregnancy increases the risk of poor health outcomes and complications. This can be linked to the hindered development of the placenta, a gestational organ responsible for nutrient and waste exchange between a mother and foetus. Primary cells obtained from an established animal model were used to examine the effects of maternal undernourishment (MUN) on placental development. A commercial human cell line was also employed to investigate how fetuin-B upregulation may play a role in placental insufficiency observed during MUN. MUN was found to increase oxidative stress and fetuin-B in the placenta, which in turn reduced placental stem cell pools and promoted mitochondrial dysfunction. Our study sheds light on the mechanisms responsible for MUN-induced placental insufficiency while identifying therapeutic agents as possible add-on interventions.
DOI: 10.6084/m9.figshare.28749639
title: The long noncoding RNA CCDC144NL-AS1: prognosis significance and potential biological functions in cervical carcinoma

description: Recent research has shown that long noncoding RNA (lncRNA) performs a critical regulatory function across multiple malignancies. The involvement of RNA in the progression of multiple human cancer types has been elucidated; however, there is limited understanding regarding the importance of the lncRNA CCDC144NL-AS1 in cervical carcinoma (CC). CCDC144NL-AS1 expression was measured in 86 CC samples by RT-PCR. CC cell lines were engineered with CCDC144NL-AS1 overexpression using plasmid vectors, allowing for the exploration of its impact on the migration of tumour cells. Additionally, we studied how CCDC144NL-AS1 impacts epithelial-mesenchymal transition signalling, focusing on its expression levels and functional roles. CCDC144NL-AS1 expression showed a notable increase in gynaecological tumour specimens and cell lines in contrast to normal control (all <i>p</i> &lt; 0.05). This expression exhibited relationships with the clinical stage (<i>p</i> = 0.003), histologic grade (<i>p</i> = 0.020), and lymph node metastasis (<i>p</i> = 0.013). Additionally, survival rates were found to be lower in CC patients with increased CCDC144NL-AS1 expression, as confirmed by multivariate analysis, compared to individuals with reduced expression levels (Hazard ratio = 1.960; <i>p</i> = 0.020). CCDC144NL-AS1 also facilitated increased cell viability and migration while triggering the EMT pathway. Xenograft models demonstrated that lower CCDC144NL-AS1 levels resulted in smaller tumours and longer survival (median survival: 43.5 vs. 35.5 days, <i>p</i> &lt; 0.05). CCDC144NL-AS1 significantly influences cell migration, making it a promising target for CC treatment and a valuable prognostic indicator. LncRNAs could be utilised as biomarkers for cancer diagnosis and prognosis. While accumulating research points to the involvement of CCDC144NL-AS1, a type of lncRNA, in various tumours, its study in cervical carcinoma has been minimal. We carried out a targeted analysis of CCDC144NL-AS1 expression in cervical carcinoma tissues using RT-qPCR. Further assessments of its role in cell migration were made through CCK-8 assays, Wound-healing, and xenograft experiments. Functional assays indicated that CCDC144NL-AS1 acts as a tumour promoter in cervical carcinoma, with higher expression associated with tumour progression and a poor prognosis. Our findings provide the first comprehensive understanding of CCDC144NL-AS1’s role in cervical carcinoma, highlighting it as a potential therapeutic target and prognostic marker.
DOI: 10.6084/m9.figshare.28749639.v1
title: The long noncoding RNA CCDC144NL-AS1: prognosis significance and potential biological functions in cervical carcinoma

description: Recent research has shown that long noncoding RNA (lncRNA) performs a critical regulatory function across multiple malignancies. The involvement of RNA in the progression of multiple human cancer types has been elucidated; however, there is limited understanding regarding the importance of the lncRNA CCDC144NL-AS1 in cervical carcinoma (CC). CCDC144NL-AS1 expression was measured in 86 CC samples by RT-PCR. CC cell lines were engineered with CCDC144NL-AS1 overexpression using plasmid vectors, allowing for the exploration of its impact on the migration of tumour cells. Additionally, we studied how CCDC144NL-AS1 impacts epithelial-mesenchymal transition signalling, focusing on its expression levels and functional roles. CCDC144NL-AS1 expression showed a notable increase in gynaecological tumour specimens and cell lines in contrast to normal control (all <i>p</i> &lt; 0.05). This expression exhibited relationships with the clinical stage (<i>p</i> = 0.003), histologic grade (<i>p</i> = 0.020), and lymph node metastasis (<i>p</i> = 0.013). Additionally, survival rates were found to be lower in CC patients with increased CCDC144NL-AS1 expression, as confirmed by multivariate analysis, compared to individuals with reduced expression levels (Hazard ratio = 1.960; <i>p</i> = 0.020). CCDC144NL-AS1 also facilitated increased cell viability and migration while triggering the EMT pathway. Xenograft models demonstrated that lower CCDC144NL-AS1 levels resulted in smaller tumours and longer survival (median survival: 43.5 vs. 35.5 days, <i>p</i> &lt; 0.05). CCDC144NL-AS1 significantly influences cell migration, making it a promising target for CC treatment and a valuable prognostic indicator. LncRNAs could be utilised as biomarkers for cancer diagnosis and prognosis. While accumulating research points to the involvement of CCDC144NL-AS1, a type of lncRNA, in various tumours, its study in cervical carcinoma has been minimal. We carried out a targeted analysis of CCDC144NL-AS1 expression in cervical carcinoma tissues using RT-qPCR. Further assessments of its role in cell migration were made through CCK-8 assays, Wound-healing, and xenograft experiments. Functional assays indicated that CCDC144NL-AS1 acts as a tumour promoter in cervical carcinoma, with higher expression associated with tumour progression and a poor prognosis. Our findings provide the first comprehensive understanding of CCDC144NL-AS1’s role in cervical carcinoma, highlighting it as a potential therapeutic target and prognostic marker.
DOI: 10.48597/fbm8-7at7
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.6084/m9.figshare.30061822
title: The influence of high maternal body mass index (≥35 kg/m<sup>2</sup>) on haemodynamic parameters during pregnancy: a prospective observational study

description: Maternal obesity is a growing global health concern, yet its impact on maternal haemodynamic throughout pregnancy remains underexplored. We investigated haemodynamic adaptations across gestation in women with high body mass index (BMI) (≥35 kg/m<sup>2</sup>) and results were compared to low-risk controls (BMI 18.5–24.9 kg/m<sup>2</sup>). This prospective observational study used non-invasive cardiac output monitoring (NICOM; Baxter Healthcare, Deerfield, IL) to assess maternal haemodynamic parameters, including cardiac output (CO), stroke volume (SV), total peripheral resistance (TPR), systolic blood pressure (sBP) and mean arterial pressure (MAP) in pregnant women with high BMI. Assessments were carried out across five gestational windows (11–19 + 6, 20–27 + 6, 28–33 + 6, 34–37 + 6 and ≥38 weeks). Results were compared to low-risk healthy controls (BMI 18.5–24.9 kg/m<sup>2</sup>). A total of 329 women were recruited, including 125 with high BMI and 189 controls. Across all gestational windows, women with high BMI consistently demonstrated significantly higher CO and SV. Compared to controls, median CO was high among women with high BMI, at 11–19 + 6 weeks [8.8 L/min (IQR 7.2–9.9) versus 6.7 L/min (5.8–7.6); <i>p</i> &lt; .001]; median SV was 104.2 mL (93.7–124.9) versus 81.9 mL (74.3–94.0) (<i>p</i> &lt; .001). This trend persisted at later gestations. In contrast, median TPR was significantly lower in the high BMI group; at 28–33 + 6 weeks, 847 dyn·s·cm<sup>−5</sup> (unit of measurement of TPR: dynes·seconds per centimetre to the fifth power) (783–937) versus 1083 (924–1161) in the controls (<i>p</i> &lt; .001). Despite reduced TPR, sBP and MAP were higher in women with high BMI throughout pregnancy. Heart rate (HR) and diastolic blood pressure (dBP) did not differ significantly between groups at any gestational window. Pregnant women with high BMI have a distinctive haemodynamic profile characterised by high CO with a compensatory reduction in TPR. Further research is required to assess the risk of placental mediated diseases in that group. Maternal obesity affects a growing number of pregnancies, but its impact on maternal heart function and blood flow throughout pregnancy is not fully understood. In our study, we measured heart function in pregnant women with high body mass index (BMI ≥35 kg/m<sup>2</sup>) and compared these results to healthy women with normal BMI. Women with high BMI had stronger heart output and greater blood volume during pregnancy. Despite having lower resistance in their blood vessels, these women also had higher blood pressure. These findings highlight important cardiovascular changes linked to obesity in pregnancy, suggesting that specialised monitoring could improve health outcomes for these women and their babies.
DOI: 10.6084/m9.figshare.30061822.v1
title: The influence of high maternal body mass index (≥35 kg/m<sup>2</sup>) on haemodynamic parameters during pregnancy: a prospective observational study

description: Maternal obesity is a growing global health concern, yet its impact on maternal haemodynamic throughout pregnancy remains underexplored. We investigated haemodynamic adaptations across gestation in women with high body mass index (BMI) (≥35 kg/m<sup>2</sup>) and results were compared to low-risk controls (BMI 18.5–24.9 kg/m<sup>2</sup>). This prospective observational study used non-invasive cardiac output monitoring (NICOM; Baxter Healthcare, Deerfield, IL) to assess maternal haemodynamic parameters, including cardiac output (CO), stroke volume (SV), total peripheral resistance (TPR), systolic blood pressure (sBP) and mean arterial pressure (MAP) in pregnant women with high BMI. Assessments were carried out across five gestational windows (11–19 + 6, 20–27 + 6, 28–33 + 6, 34–37 + 6 and ≥38 weeks). Results were compared to low-risk healthy controls (BMI 18.5–24.9 kg/m<sup>2</sup>). A total of 329 women were recruited, including 125 with high BMI and 189 controls. Across all gestational windows, women with high BMI consistently demonstrated significantly higher CO and SV. Compared to controls, median CO was high among women with high BMI, at 11–19 + 6 weeks [8.8 L/min (IQR 7.2–9.9) versus 6.7 L/min (5.8–7.6); <i>p</i> &lt; .001]; median SV was 104.2 mL (93.7–124.9) versus 81.9 mL (74.3–94.0) (<i>p</i> &lt; .001). This trend persisted at later gestations. In contrast, median TPR was significantly lower in the high BMI group; at 28–33 + 6 weeks, 847 dyn·s·cm<sup>−5</sup> (unit of measurement of TPR: dynes·seconds per centimetre to the fifth power) (783–937) versus 1083 (924–1161) in the controls (<i>p</i> &lt; .001). Despite reduced TPR, sBP and MAP were higher in women with high BMI throughout pregnancy. Heart rate (HR) and diastolic blood pressure (dBP) did not differ significantly between groups at any gestational window. Pregnant women with high BMI have a distinctive haemodynamic profile characterised by high CO with a compensatory reduction in TPR. Further research is required to assess the risk of placental mediated diseases in that group. Maternal obesity affects a growing number of pregnancies, but its impact on maternal heart function and blood flow throughout pregnancy is not fully understood. In our study, we measured heart function in pregnant women with high body mass index (BMI ≥35 kg/m<sup>2</sup>) and compared these results to healthy women with normal BMI. Women with high BMI had stronger heart output and greater blood volume during pregnancy. Despite having lower resistance in their blood vessels, these women also had higher blood pressure. These findings highlight important cardiovascular changes linked to obesity in pregnancy, suggesting that specialised monitoring could improve health outcomes for these women and their babies.
DOI: 10.6084/m9.figshare.30860140.v1
title: Prognostic value of systemic immune-inflammation index in cervical cancer: a systematic review and meta-analysis

description: A growing body of evidence indicates that the systemic immune-inflammation index (SII) is associated with the prognosis of cervical cancer (CC). However, its prognostic value remains controversial. This study aimed to comprehensively evaluate the performance of SII in predicting the prognosis of CC. Studies on the prognostic potential of SII in CC were acquired from PubMed, Embase, Web of Science, and the Cochrane Library from database inception to July 4, 2024. Outcome measures included progression-free survival (PFS), overall survival (OS), relapse-free survival (RFS), and complete response (CR), which were expressed as hazard ratio (HR) and 95% confidence interval (CI). Sensitivity and subgroup analyses were carried out to evaluate the stability of results and identify potential sources of heterogeneity. Ten cohort studies involving 2007 patients were included in the meta-analysis. High SII levels were significantly associated with reduced OS (HR = 2.45; 95% CI: 1.56–3.86, <i>p</i> = 0.001), PFS (HR = 2.93; 95% CI: 1.88–4.58, <i>p</i> &lt; 0.00001), and CR (HR = 0.23, 95% CI: 0.11–0.50; <i>p</i> = 0.0002) in patients with CC. Subgroup analyses suggested that SII was more effective in predicting outcomes in Asian patients with CC. High SII levels are significantly associated with reduced OS, PFS, and CR in CC. Therefore, SII is a promising biomarker for predicting outcomes and informing treatment decisions for immunotherapy in CC. The systemic immuno-inflammation index (SII), a blood parameter derived from platelet, neutrophil, and lymphocyte counts, is hypothesised to correlate with cancer patient prognosis. Despite this, its prognostic relevance in cervical cancer remains a subject of debate. Our study presents a pioneering systematic review and meta-analysis of the prognostic significance of SII in the context of cervical cancer within large datasets, thoroughly examining the correlation between pre-treatment SII levels and survival outcomes among cervical cancer patients. This study analysed data across 10 studies encompassing 2007 patients. Our findings indicate that, in contrast to those with low SII, patients exhibiting high SII levels experienced reduced overall and progression-free survival rates, along with a decreased likelihood of attaining complete remission. These findings underscore that elevated pre-treatment SII values are significantly linked to an adverse prognosis in cervical cancer patients. SII may serve as a robust biomarker for the identification of patients at high risk for poor prognosis, facilitating the development of personalised therapeutic approaches.
DOI: 10.48597/n3sd-wx58
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/t4wh-hpmb
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.6084/m9.figshare.30860140
title: Prognostic value of systemic immune-inflammation index in cervical cancer: a systematic review and meta-analysis

description: A growing body of evidence indicates that the systemic immune-inflammation index (SII) is associated with the prognosis of cervical cancer (CC). However, its prognostic value remains controversial. This study aimed to comprehensively evaluate the performance of SII in predicting the prognosis of CC. Studies on the prognostic potential of SII in CC were acquired from PubMed, Embase, Web of Science, and the Cochrane Library from database inception to July 4, 2024. Outcome measures included progression-free survival (PFS), overall survival (OS), relapse-free survival (RFS), and complete response (CR), which were expressed as hazard ratio (HR) and 95% confidence interval (CI). Sensitivity and subgroup analyses were carried out to evaluate the stability of results and identify potential sources of heterogeneity. Ten cohort studies involving 2007 patients were included in the meta-analysis. High SII levels were significantly associated with reduced OS (HR = 2.45; 95% CI: 1.56–3.86, <i>p</i> = 0.001), PFS (HR = 2.93; 95% CI: 1.88–4.58, <i>p</i> &lt; 0.00001), and CR (HR = 0.23, 95% CI: 0.11–0.50; <i>p</i> = 0.0002) in patients with CC. Subgroup analyses suggested that SII was more effective in predicting outcomes in Asian patients with CC. High SII levels are significantly associated with reduced OS, PFS, and CR in CC. Therefore, SII is a promising biomarker for predicting outcomes and informing treatment decisions for immunotherapy in CC. The systemic immuno-inflammation index (SII), a blood parameter derived from platelet, neutrophil, and lymphocyte counts, is hypothesised to correlate with cancer patient prognosis. Despite this, its prognostic relevance in cervical cancer remains a subject of debate. Our study presents a pioneering systematic review and meta-analysis of the prognostic significance of SII in the context of cervical cancer within large datasets, thoroughly examining the correlation between pre-treatment SII levels and survival outcomes among cervical cancer patients. This study analysed data across 10 studies encompassing 2007 patients. Our findings indicate that, in contrast to those with low SII, patients exhibiting high SII levels experienced reduced overall and progression-free survival rates, along with a decreased likelihood of attaining complete remission. These findings underscore that elevated pre-treatment SII values are significantly linked to an adverse prognosis in cervical cancer patients. SII may serve as a robust biomarker for the identification of patients at high risk for poor prognosis, facilitating the development of personalised therapeutic approaches.
DOI: 10.48597/zexd-rvfs
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/3dnt-3un5
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/54jm-mdgp
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/5vch-x5td
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/7wha-dbep
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.17639/nott.7625
title: Improving tic services in England (INTEND) survey data

description: The ImproviNg Tic services in EnglaND (INTEND) study explored current service provision for tics and Tourette syndrome in England by contacting NHS organisations. We also asked healthcare professionals working in children and young people’s services about their experience of assessing and treating tics and whether they felt they would benefit from more training in this area. We then worked with experts throughout England to develop a recommended care pathway for the referral, assessment and treatment of tics. Responses from NHS organisations demonstrated that tic service provision was inconsistent and very limited across England. Only 12 service providers were identified as providing a full care pathway that offered both assessment and treatment, and 5 of these providers were located in London. The national survey was completed by 184 healthcare professionals. They highlighted a lack of resources, including funding, training and national clinical guidelines for tics. Most survey respondents identified a need for further resources to support them with both assessing and treating tics, including training. FOI and national survey responses together emphasised that tic services need urgent improvement. Experts rated 62 service features on their level of importance to include within a care pathway. Based on these ratings and a team workshop, a final 43 service features were approved to guide the design of the care pathway. Our Patient and Public Involvement (PPI) panel consisting of ten parents/carers of young people with tics provided vital input throughout the study. They shared feedback on study findings, including how findings reflected their personal lived experiences. Their input on key aspects of the INTEND Pathway also ensured that its design suited the needs of young people with tics and their families.
DOI: 10.48597/8fu8-8e9f
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/jcn8-px34
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/4ew5-3969
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/xy3v-94k9
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/6x5r-xrdg
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)